Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tavokinogene telseplasmid
- Development stage
- Phase 2
- Lead developer
- OncoSec Medical
- Modality
- Gene Therapies
- Administration
- Intratumoral
01
Overview
Tavokinogene telseplasmid is a synthetic DNA plasmid encoding the human interleukin 12 (hIL‑12) protein, specifically both the p35 and p40 subunits, separated by an internal ribosome entry site and under control of a cytomegalovirus promoter. It is delivered via intratumoral injection followed by electroporation to enable local expression of IL‑12 in the tumor microenvironment. The expressed IL‑12 acts as an immunostimulant, enhancing anti-tumor immune responses by promoting activation of cytotoxic T cells and natural killer cells. Tavokinogene telseplasmid is being developed primarily for various cancers including malignant melanoma, Merkel cell carcinoma, cutaneous T-cell lymphoma, head and neck cancer, and triple negative breast cancer. The drug has orphan designation for malignant melanoma[1][2][3][5][6].
- Brand names
- TAVO
- Other names
- tavokinogene telseplasmidpIL-12pIL12pIL 12
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on tavokinogene telseplasmid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tavokinogene telseplasmid.